Shuo Ma
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 80
-
- Lymphoma Diagnosis and Treatment 53
- Immunology and Allergy top 2%
- Immunology top 5%
- Immunodeficiency and Autoimmune Disorders 13
- Cancer Research top 5%
- MicroRNA in disease regulation 8
- Cancer-related molecular mechanisms research 8
-
- Viral-associated cancers and disorders 15
-
- Advanced Breast Cancer Therapies 12
-
- Circular RNAs in diseases 10
- Co-authors
- Rex L. ChisholmCharles A. ParkosSunil K. ShawFrancis W. LuscinskasAsma NusratQijun QianXinyue WangSteven T. Rosen
- Partner nations
- United StatesChinaAustralia
In The Last Decade
Shuo Ma
147 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 133
- Genetics 909
- Pathology and Forensic Medicine 898
- Immunology and Allergy 238
- Immunology 733
- Cancer Research 500
Countries citing papers authored by Shuo Ma
This map shows the geographic impact of Shuo Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuo Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuo Ma more than expected).
Fields of papers citing papers by Shuo Ma
This network shows the impact of papers produced by Shuo Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuo Ma. The network helps show where Shuo Ma may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shuo Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 9 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 0 | |
| 8 | 2024 | 0 | |
| 9 | 2023 | 7 | |
| 10 | 2023 | 6 | |
| 11 | 2023 | 1 | |
| 12 | 2023 | 12 | |
| 13 | 2023 | 3 | |
| 14 | 2023 | 1 | |
| 15 | 2022 | 1 | |
| 16 | 2021 | 27 | |
| 17 | 2020 | 27 | |
| 18 | Current Progress in CAR-T Cell Therapy for Solid Tumors | 2019 | 2 |
| 19 | 2015 | 16 | |
| 20 | 2004 | 121 |
About Shuo Ma
Shuo Ma is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology, Oncology and Cancer Research, having authored 160 papers that have together received 3.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (80 papers), Lymphoma Diagnosis and Treatment (53 papers), Viral-associated cancers and disorders (15 papers), Immunodeficiency and Autoimmune Disorders (13 papers), Advanced Breast Cancer Therapies (12 papers), Circular RNAs in diseases (10 papers), MicroRNA in disease regulation (8 papers) and Cancer-related molecular mechanisms research (8 papers). The work is most often cited by research in Genetics (909 citations), Pathology and Forensic Medicine (898 citations), Immunology and Allergy (238 citations), Immunology (733 citations) and Cancer Research (500 citations). Shuo Ma has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Rex L. Chisholm, Charles A. Parkos, Sunil K. Shaw, Francis W. Luscinskas, Asma Nusrat, Qijun Qian, Xinyue Wang, Steven T. Rosen, Zhong Li and Changzheng Zhang. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Current Hematologic Malignancy Reports and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.